160664-95-9

Basic information

• Product Name: 5-HYDRAZINO-2-METHOXYPYRIDINE
• Synonyms: 5-HYDRAZINO-2-METHOXYPYRIDINE;Pyridine,5-hydrazino-2-methoxy;Pyridine, 5-hydrazino-2-methoxy- (9CI);Pyridine,5-hydrazinyl-2-methoxy-;5-Hydrazine-2-methoxypyridine;5-hydrazinyl-2-Methoxy-Pyridine;(6-Methoxy-pyridin-3-yl)-hydrazine
• CAS NO: 160664-95-9
• Molecular Formula: C₆H₉N₃O
• Molecular Weight: 139.15516
• Product Categories: PYRIDINE;Pyridines
• Mol File: 160664-95-9.mol

Chemical Properties

• Melting Point: 64 °C
• Boiling Point: 284℃
• Flash Point: 125℃
• Appearance: /
• Density: 1.228
• Vapor Pressure: 0.003mmHg at 25°C
• Refractive Index: 1.615
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• PKA: 4.60±0.24(Predicted)
• CAS DataBase Reference: 5-HYDRAZINO-2-METHOXYPYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-HYDRAZINO-2-METHOXYPYRIDINE(160664-95-9)
• EPA Substance Registry System: 5-HYDRAZINO-2-METHOXYPYRIDINE(160664-95-9)

Safety Data

• Hazardous Substances Data: 160664-95-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-HYDRAZINO-2-METHOXYPYRIDINE is used as an intermediate in the synthesis of pharmaceuticals for its potential antitumor properties. It contributes to the development of drugs that target cancer cells, offering a promising avenue for cancer treatment.
Used in Agrochemical Industry:
5-HYDRAZINO-2-METHOXYPYRIDINE is used as a building block in the synthesis of agrochemicals, particularly for its potential antifungal properties. It aids in the creation of fungicides that protect crops from fungal infections, thereby ensuring agricultural productivity.
Used in Heterocyclic Compound Production:
5-HYDRAZINO-2-METHOXYPYRIDINE is used as a key component in the production of various heterocyclic compounds. Its unique structure allows for the formation of complex molecules with diverse applications in chemical and pharmaceutical industries.
Used in Material Development:
5-HYDRAZINO-2-METHOXYPYRIDINE is utilized in the research and development of new materials. Its properties are harnessed to create innovative materials with potential applications in various fields, including electronics, coatings, and advanced composites.
Used in Organic Synthesis:
5-HYDRAZINO-2-METHOXYPYRIDINE is employed as a reactant in organic synthesis processes. Its reactivity and functional groups make it a versatile building block for the creation of a wide range of organic compounds with specific properties and applications.

InChI:InChI=1/C6H9N3O/c1-10-6-3-2-5(9-7)4-8-6/h2-4,9H,7H2,1H3

Upstream product

• 6628-77-9 6-methoxy-pyridin-3-ylamine 
• 179543-88-5 5-hydrazinyl-2-methoxypyridine hydrochloride 

Downstream Products

• 741286-30-6 5-(4-chlorophenyl)-1-(6-methoxy-3-pyridyl)pyrazole-3-carboxylic acid ethyl ester 
• 179543-88-5 5-hydrazinyl-2-methoxypyridine hydrochloride 
• 858597-96-3 5-(5-benzyloxy-2-pyridyl)-1-(6-methoxy-3-pyridyl)-1H-pyrazole-3-carboxylic acid ethyl ester 
• 875553-66-5 1-(6-methoxy-3-pyridyl)-5-(1-methyl-5-phenylthio-1H-1, 2, 4-triazol-3-yl)-1H-pyrazole-3-carboxylic acid ethyl ester 
• 858600-39-2 1-(6-methoxy-3-pyridyl)-5-{1-[(4-methylphenyl)sulfonyl]-1H-pyrazol-3-yl}-1H-pyrazole-3-carboxylic acid ethyl ester 
• 1196056-02-6 2-(5-methoxy-1H-pyrrolo[3,2-b]pyridin-3-yl)ethanol 
• 1196055-99-8 5-methoxy-3-phenyl-1H-pyrrolo[3,2-b]pyridine 
• 741286-32-8 5-(4-chlorophenyl)-1-(6-methoxy-pyridin-3-yl)pyrazole-3-carboxylic acid 
• 741286-89-5 5-(4-methoxyphenyl)-1-(6-methoxy-pyridin-3-yl)pyrazole-3-carboxylic acid 
• 741286-88-4 5-(4-Methoxyphenyl)-1-(6-methoxy-pyridin-3-yl)pyrazole-3-carboxylic acid ethyl ester 
• 741291-47-4 1-(6-methoxy-3-pyridyl)-5-(3-methylphenyl)pyrazole-3-carboxylic acid ethyl ester 
• 874484-20-5 S29434 

Relevant articles and documents

S29434, a quinone reductase 2 inhibitor: Main biochemical and cellular characterization

Quinone reductase 2 (QR2, E.C. 1.10.5.1) is an enzyme with a feature that has attracted attention for several decades: in standard conditions, instead of recognizing NAD(P)H as an electron donor, it recognizes putative metabolites of NADH, such as N-methyl- and N-ribosyl-dihydronicotinamide. QR2 has been particularly associated with reactive oxygen species and memory, strongly suggesting a link among QR2 (as a possible key element in pro-oxidation), autophagy, and neurodegeneration. In molecular and cellular pharmacology, understanding physiopathological associations can be difficult because of a lack of specific and powerful tools. Here, we present a thorough description of the potent, nanomolar inhibitor [2-(2-methoxy-5H-1,4b,9-triaza(indeno[2,1-a]inden-10-yl)ethyl]-2-furamide (S29434 or NMDPEF; IC505 5–16 nM) of QR2 at different organizational levels. We provide full detailed syntheses, describe its cocrystallization with and behavior at QR2 on a millisecond timeline, show that it penetrates cell membranes and inhibits QR2-mediated reactive oxygen species (ROS) production within the 100 nM range, and describe its actions in several in vivo models and lack of actions in various ROS-producing systems. The inhibitor is fairly stable in vivo, penetrates cells, specifically inhibits QR2, and shows activities that suggest a key role for this enzyme in different pathologic conditions, including neurodegenerative diseases.

PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS

Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT 1. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R4, R5, and G, are defined herein.

Design and Synthesis of Novel Deuterated Ligands Functionally Selective for the γ-Aminobutyric Acid Type A Receptor (GABAAR) α6 Subtype with Improved Metabolic Stability and Enhanced Bioavailability

Recent reports indicate that α6β2/3γ2 GABAAR selective ligands may be important for the treatment of trigeminal activation-related pain and neuropsychiatric disorders with sensori-motor gating deficits. Based on 3 functionally α6β2/3γ2 GABAAR selective pyrazoloquinolinones, 42 novel analogs were synthesized, and their in vitro metabolic stability and cytotoxicity as well as their in vivo pharmacokinetics, basic behavioral pharmacology, and effects on locomotion were investigated. Incorporation of deuterium into the methoxy substituents of the ligands increased their duration of action via improved metabolic stability and bioavailability, while their selectivity for the GABAAR α6 subtype was retained. 8b was identified as the lead compound with a substantially improved pharmacokinetic profile. The ligands allosterically modulated diazepam insensitive α6β2/3γ2 GABAARs and were functionally silent at diazepam sensitive α1β2/3γ2 GABAARs, thus no sedation was detected. In addition, these analogs were not cytotoxic, which render them interesting candidates for treatment of CNS disorders mediated by GABAAR α6β2/3γ2 subtypes.

LIGANDS SELECTIVE TO ALPHA 6 SUBUNIT-CONTAINING GABAA RECEPTORS ANS THEIR METHODS OF USE

Provided herein are novel pyrazoloquinolinone compounds and method of using such compounds to treat disorders such as neuropsychiatric disorders with sensorimotor gating deficits, such as schizophrenia, tic disorders, attention deficit hyperactivity disorder, obsessive compulsive disorder, panic disorder, Huntington's disease and nocturnal enuresis;depression; temporomandibular myofascial pain; disorders of trigeminal nerve, such as trigeminal neuralgia and trigeminal neuropathy; migraine; and tinnitus.

NEW POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR

The present invention relates to compounds useful in therapy, to compositions comprising said compounds, and to methods of treating diseases comprising administration of said compounds. The compounds referred to are positive allosteric modulators (PAMs) of the nicotinic acetylcholine alpha7 receptor.

HEPATITIS C INHIBITOR COMPOUNDS

A compound of formula (I) useful for the treatment or prevention of hepatitis C viral infection, (Formula (I)) wherein: X1 and X2 are each independently CRB or N; RB is H, (C1-6)alkyl, (C1-6/sub

TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS

The invention relates to tetrazole compounds of formula (I) wherein X, Y, Z, R1, R2 and R3 are as described in the description; to pharmaceutically acceptable salts thereof, and to the use of such compounds use as medicaments, especially as orexin receptor antagonists.

TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS

The invention relates to tetrazole compounds of formula (I) wherein X, Y, Z, R1, R2 and R3 are as described in the description; to pharmaceutically acceptable salts thereof, and to the use of such compounds use as medicaments, especially as orexin receptor antagonists.

Synthesis of 4- and 6-azaindoles via the fischer reaction

Contrary to the common idea that Fischer indole cyclization often cannot be effectively applied to the synthesis of the corresponding azaindoles, we show that this approach can be actually very efficient for the formation of 4- and 6-azaindoles bearing an electron-donating group on the starting pyridylhydrazines. Two 4-azaindole natural product analogues were synthesized in a few steps and very good overall yields.

PYRAZOLE DERIVATIVE

A compound represented by Formula (I): wherein Ar1 represents Formula (II): Ar2 represents a 5- or 6-membered aromatic heterocyclic group which may be substituted; and X represents Formula (III): a salt thereof, or a solvate of the compound or the salt. A potent platelet aggregation suppressant which does not inhibit COX-1 and COX-2 is provided.